POLA2
ENSG00000014138
Target class
Enzyme
Chromosome
11
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- FLJ21662
- Target name
- POLA2
- Gene name
- DNA polymerase alpha 2, accessory subunit
- Gene symbol
- POLA2
- Protein name
- DNA polymerase alpha subunit B (DNA polymerase alpha 70 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 34.89
- Tissue specificity (Gini)
- 0.336
- Tissue specificity (tau)
- 0.808
- KEGG gene identifiers
- hsa:23649
- Protein interaction confidence
- 0.884571
- Protein interaction partners
- 56
- R-HSA-113501
- R-HSA-174411
- R-HSA-174430
- R-HSA-68952
- R-HSA-68962
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- R-HSA-9710421
- End position
- 65305959
- Start position
- 65261913
- Chromosome
- 11
- Strand
- Forward
- Nucleus.
- Nucleoplasm
- Tissue specificity (tau)
- 0.808238
- Expression inequality (Gini)
- 0.33611
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 34.89
- Testis
- 14.58
- Spleen
- 14.33
- Ovary
- 12.48
- Uterus
- 12.02
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes34.89
- Testis14.58
- Spleen14.33
- Ovary12.48
- Uterus12.02
- Cervix - Endocervix11.53
- Fallopian Tube11.3
- Esophagus - Muscularis11.29
- Cervix - Ectocervix10.58
- Esophagus - Gastroesophageal Junction10.49
- Cells - Cultured fibroblasts10.11
- Small Intestine - Terminal Ileum9.98
- Lung9.6
- Vagina9.57
- Brain - Cerebellar Hemisphere9.16
- Prostate9
- Brain - Cerebellum9
- Thyroid8.93
- Nerve - Tibial8.78
- Bladder8.48
- Esophagus - Mucosa8.29
- Skin - Sun Exposed (Lower leg)7.67
- Colon - Sigmoid7.67
- Breast - Mammary Tissue7.3
- Colon - Transverse7.09
And 29 more, listed on the interactive page.
- GO:0006269
- GO:0006270
- GO:0005654
- GO:0005658
Molecular functions
- GO:0005515
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor